Aims: To describe the number, type and location of ophthalmic companies and their associated product areas and indications. Methods: A retrospective, non-patient-based, observational review of ophthalmic pharmaceutical and device companies with a new product in development. Data was compiled by Internet searches. Results: We identified 190 companies currently developing ophthalmic products: 134 (71%) were privately held and 56 (29%) publicly held, while 136 (72%) were in the United States and 53 (28%) were outside the United States. There were 436 total products of which 338 (78%) were pharmaceuticals and 98 (22%) devices. With pharmaceuticals we identified 46 separate indications with age-related macular degeneration (n = 75), glaucoma (n = 52) and dry eye (n = 46) as most common; anti-vascular endothelial growth factor, hormone therapy and anti-inflammatory products were also common classes. With devices there were 30 indications with glaucoma (n = 26), age-related macular degeneration (n = 19) and dry eye (n = 6) as most common; drug delivery, ocular implants and prostheses were less common classes. Conclusions: Ophthalmology as a specialty is benefited by a wide effort in new medicine and device development. However, a concentration of effort into relatively few indications suggests a potential lack of market analysis and possible difficulty for many companies in commercializing their product.

2.
Reichert JM: Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2003;2:695-702.
5.
Stewart WC, Stewart JA, Kruft B, Nelson LA: Challenges facing ophthalmic start-up companies in developing new devices or medicines. Acta Ophthalmol 2013;91:81-83.
6.
Goodman CS, Gelijns AC: The changing environment for technological innovation in health care. Baxter Health Policy Rev 1996;2:267-315.
10.
Global recession knocks start-ups. http://news.bbc.co.uk/2/hi/8455361.stm.
11.
Stewart WC, Chaney PG, Stewart JA, Kruft B, Nelson LA: Qualitative factors underlying the successful investment in new ophthalmic pharmaceutical products in the United States. Acta Ophthalmol 2013;94:496-497.
12.
The innovation gap in pharmaceutical drug discovery and new models for R&D success. http://www.kellogg.northwestern.edu/biotech/faculty/articles/newrdmodel.pdf.
13.
Peters TJ, Waterman RH: In Search of Excellence: Lessons from America's Best-Run Companies. New York, Harper & Row, 1982.
14.
Shafiee A, Bucolo C, Budzynski E, Ward KW, López FJ: In vivo ocular efficacy profile of mapracorat, a novel selective glucocorticoid receptor agonist, in rabbit models of ocular disease. Invest Ophthalmol Vis Sci 2011;52:1422-1430.
15.
Stewart WC, Crean CS, Zink RC, Brubaker K, Haque RM, Hwang DG: Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Am J Ophthalmol 2010;150:744-751.
16.
Baiula M, Spartà A, Bedini A, Carbonari G, Bucolo C, Ward KW, Zhang JZ, Govoni P, Spampinato S: Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist. Mol Vis 2011;17:3208-3223.
17.
Collier R: Drug development cost estimates hard to swallow. CMAJ 2009;180:279-280.
18.
Medical device makers spend millions to meet FDA rules, study finds. http://medcitynews.com/2010/11/medical-device-makers-spend-millions-to-meet-fda-rules-study-finds/.
19.
Collins J: Good to Great: Why Some Companies Make the Leap… and Others Don't. New York, Harper Business, 2001.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.